← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Neuropace, Inc.
Mountain View, CA
$9,737,772
Total funding
1
Grants
Funding over time
peak $3M · FY2021–25$5M$3.8M$2.5M$1.3M$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,737,772 · 1
By mechanism
UH3$9,737,772 · 1
Investigators at Neuropace, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Not enough data
Largest grants
Thalamocortical Responsive Neurostimulation for the Treatment of Lennox-Gastaut Syndrome$2,959,252
UH3 · FY2023 · NS
Thalamocortical Responsive Neurostimulation for the Treatment of Lennox-Gastaut Syndrome$2,596,763
UH3 · FY2022 · NS
Thalamocortical Responsive Neurostimulation for the Treatment of Lennox-Gastaut Syndrome$1,710,919
UH3 · FY2024 · NS
Thalamocortical Responsive Neurostimulation for the Treatment of Lennox-Gastaut Syndrome$1,609,057
UH3 · FY2025 · NS
Thalamocortical Responsive Neurostimulation for the Treatment of Lennox-Gastaut Syndrome$831,388
UH3 · FY2021 · NS
Thalamocortical Responsive Neurostimulation for the Treatment of Lennox-Gastaut Syndrome$30,393
UH3 · FY2022 · NS